Vertaling van "adverse effects medline case report " (Nederlands → Frans) :

Table 3: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)
Table 5: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)

Table 2: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words
Table 4: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

Both the SCF’s 2003 opinion and the advisory report recently published by the German Federal Institute for Risk Assessment (BfR, 2008) mention a number of observation cases and reported cases with acute adverse effects, including death, in people who consume energy drinks.
L’avis du SCF de 2003 ainsi que l’avis récemment émis par l’Institut fédéral allemand d’évaluation des risques (BfR, 2008) mentionnent un certain nombre de cas d’observation et de cas rapportés signalant des effets nocifs aigus, comprenant des décès, chez des sujets consommant des boissons énergisantes.

The evaluation of oncological adverse effects (as well as the evaluation of the Periodic Safety Update Report – PSUR, Annual Safety Report - ASR, Suspected Unexpected Serious Adverse Reaction
The evaluation of oncological adverse effects (as well as the evaluation of the Periodic Safety Update Report – PSUR, Annual Safety Report - ASR, Suspected Unexpected Serious Adverse Reaction

Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.
Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.

At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.
At the end of 2007 the FAMHP initiated a programme for specific monitoring of new medicines (“black triangle” – symbol included in the BCFI-CBIP annotated drugs formulary – Gecommentarieerd Geneesmiddelenrepertorium – Répertoire Commenté des Médicaments) with the aim of encouraging healthcare professionals to report adverse effects of medicines with a new active substance to the FAMHP.

A final element that needs to be added to this file is the very recent report of the French toxicovigilance co-ordination committee (Comité de Coordination de Toxicovigilance Français – CCTF) (CCTF, 2009). It describes the results of the prospective follow-up of the adverse effects of consuming energy drinks, especially during the five months that passed after the most famous of these drinks was allowed to be marketed in France (15 July 2008).
Un dernier élément à verser au dossier est le très récent rapport du comité de coordination de toxicovigilance français (CCTF) qui relate les résultats du suivi prospectif des effets indésirables liés à la consommation de boissons énergisantes, en particulier dans les 5 mois qui ont suivi l’autorisation de commercialisation de la plus connue d’entreelles en France (15 juillet 2008) (CCTF, 2009).

In vitrogegevens van menselijk materiaal wijzen mogelijk op enig effect op de kwaliteit van het sperma, maar in case reports met enkele SSRI’s (waaronder paroxetine) bij de mens bleek een effect op de kwaliteit van het sperma reversibel te zijn.
Des données in vitro sur du matériel humain semblent indiquer un certain effet sur la qualité du sperme; toutefois, des rapports de cas humains avec certains ISRS (dont la paroxétine) ont montré qu’un effet sur la qualité du sperme semble réversible.

In vitro gegevens met humaan materiaal kan wijzen op enig effect op de kwaliteti van sperma, maar een aantal menselijke case reports met een aantal SSRI’s (waaronder paroxetine) hebben aangetoond dat een effect op de kwaliteit van sperma reversibel blijkt te zijn.
Des données in vitro avec du matériel humain peuvent suggérer un certain effet sur la qualité du sperme, toutefois, des rapports de cas humains avec certains ISRS (y compris la paroxétine) ont montré que l'effet sur la qualité du sperme semble être réversible.